Rituxan and Secondary immunodeficiency - a phase IV clinical study of FDA data

Summary:

Secondary immunodeficiency is reported as a side effect among people who take Rituxan (rituximab), especially for people who are 10-19 old, have been taking the drug for 1 - 2 years also take Cyclophosphamide, and have Systemic lupus erythematosus.

The phase IV clinical study analyzes which people have Secondary immunodeficiency when taking Rituxan. It is created by eHealthMe based on reports of 64,282 people who have side effects when taking Rituxan from the FDA, and is updated regularly.

What is Rituxan?

Rituxan has active ingredients of rituximab. It is often used in rheumatoid arthritis. eHealthMe is studying from 64,791 Rituxan users. Check the latest studies of Rituxan.

What is Secondary immunodeficiency?

Secondary immunodeficiency (lack of immunity due to some disease) is found to be associated with 137 drugs and 161 conditions by eHealthMe. Check the latest studies of Secondary immunodeficiency.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

64,282 people reported to have side effects when taking Rituxan.
Among them, 15 people (0.02%) have Secondary immunodeficiency.

Could Rituxan cause Secondary immunodeficiency?

Among these 15 people:

How long have people been on Rituxan when they have Secondary immunodeficiency? *

What is the age of people who have Secondary immunodeficiency when taking Rituxan? *

What are other drugs people take besides Rituxan? *

What are other side effects people have besides Secondary immunodeficiency? *

Drug Ineffective: 6 people, 40.00%
Urinary Incontinence (inability to control the flow of urine and involuntary urination): 2 people, 13.33%
Pneumonia: 2 people, 13.33%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 2 people, 13.33%
Neonatal Tachypnea: 2 people, 13.33%
Lymphocytopenia Neonatal (low level of lymphocytes in neonate): 2 people, 13.33%
Hypotension (abnormally low blood pressure): 2 people, 13.33%
Foetal Exposure During Pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect): 2 people, 13.33%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 6.67%
Cellulitis (infection under the skin): 1 person, 6.67%

What are the existing conditions these people have? *

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 11 people, 73.33%
Neuropsychiatric Lupus (the various psychiatric and neurologic symptoms due to a multi system inflammatory disorder): 4 people, 26.67%
Opsoclonus Myoclonus (a rare neurological disorder of unknown causes which appears to be the result of an autoimmune process involving the nervous system): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Rituxan and have Secondary immunodeficiency?

- Check whether Secondary immunodeficiency is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rituxan:

Rituxan (64,791 reports)

Browse all side effects of Rituxan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Secondary immunodeficiency:

Secondary immunodeficiency (137 drugs)

Browse all the conditions that are associated with Secondary immunodeficiency:

Secondary immunodeficiency (161 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rituximab (the active ingredients of Rituxan) and Rituxan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.